Population Pharmacokinetic Modeling to Support Trofinetide Dosing for the Treatment of Rett Syndrome
PopPK model-based simulations confirm that weight-banded trofinetide dosing used in LAVENDER in girls and women aged 5-20 years with RTT achieved target exposure. Graphical abstract available for this article.
Authors
- Heather Bradley (ORCID: https://orcid.org/0000-0002-7667-4197)
- Kelly Maxwell
- Julie Passarell (ORCID: https://orcid.org/0000-0002-2034-6274)
- Kathie M. Bishop
- Mona Darwish
- James M. Youakim (ORCID: https://orcid.org/0000-0001-5551-8956)
Institutions
- Acadia Pharmaceuticals (United States) (US)
- Simulations Plus (United States) (US)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1007/s12325-024-03056-9
- Citations
- 3
- Primary Topic
- Genetics and Neurodevelopmental Disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.65
Funders
- ACADIA Pharmaceuticals